Tag Archives: Sanofi

Ad Agency Encourages Pharma Marketers to Reboot

By Ben Comer | Published: April 16, 2013
People tell you who they are, but we ignore it – because we want them to be who we want them to be. – Don Draper At the beginning of the Reboot Camp – held at New York City’s Alexandria Center on April 12 – Intouch Solutions’ CEO Faruk Capan declared the days of Don Draper [...]
Posted in Advertising, Agency Insight, Emerging Markets, FDA, Marketing, Patient Communication, People, Regulatory, Sales, Strategy, Technology, healthcare, leadership, patient education, social media | Also tagged , , , , , , , , , , , | 1 Comment

New Non-Profit Alliance of Big Pharma Firms

By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog | Also tagged , , , , , , , , , | Leave a comment

Sanofi's Aubagio to Square Off Against MS Injectables

By Ben Comer | Published: September 13, 2012
The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya, and Biogen Idec’s hotly anticipated BG-12, which has a PDUFA date scheduled for December 28. Both Gilenya and BG-12 are administered orally as opposed to injected, but execs at Genzyme – [...]
Posted in FDA, Regulatory, Safety, Strategy, pricing | Also tagged , , , | 2 Comments

BIO 2012: The Case for Collaboration

By Ben Comer | Published: June 19, 2012
Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”
Posted in Biotech, Europe, Events, FDA, Global, IP, People, R&D, Regulatory, Strategy, Technology, healthcare, leadership | Also tagged , , , , , , | Leave a comment

Dare to Compare: Genzyme Bets on MS

By Ben Comer | Published: April 25, 2012
Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon. Genzyme execs didn’t go so far as to reiterate former CEO Henri Termeer’s 2010 prediction of $3 billion plus in potential sales for Lemtrada (alemtuzumab), but [...]
Posted in Biotech, Events, FDA, Global, IP, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , | 1 Comment